Form 4: RA Capital Reduces Stake in Vor Biopharma

RA Capital Management has disclosed the sale of approximately 737,989 shares of Vor Biopharma Inc. across three days in April 2026.

Summary

• RA Capital Management, L.P. sold a total of 737,989 shares of Vor Biopharma (VOR) common stock between April 13 and April 15, 2026.
• The sales were executed at weighted average prices ranging from $15.97 to $16.15 per share.
• Following these transactions, the reporting entities maintain a beneficial ownership of 3,197,619 shares.
• The transactions were conducted by RA Capital Healthcare Fund, L.P., with RA Capital Management acting as the investment manager.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the significant reduction in holdings by a major institutional investor, which may signal a lack of near-term upside conviction.

Positives

• The divestment was executed at price points between $15.97 and $16.15, indicating liquidity for the stock at these levels.

Negatives

• Significant reduction in position by a major institutional shareholder and 10% owner.
• Institutional selling pressure can negatively impact short-term market sentiment for the stock.

Risks

• Potential for continued selling pressure if the institutional investor continues to reduce its position.
• Market perception of reduced confidence in the issuer by a long-term institutional partner.

Future Outlook

No specific forward-looking guidance regarding the company's operations was provided in this ownership disclosure.

Management Comments

• The reporting persons have undertaken to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that institutional divestment in the biotech sector is common for portfolio rebalancing, though it often signals a shift in long-term conviction among major stakeholders.

Comparison to Industry Standards

• Institutional selling by 10% owners is a standard regulatory disclosure event.
• The scale of the sale is consistent with typical portfolio management activities for large healthcare-focused investment firms.

Related Party Transactions

• The reporting persons are affiliated with Dr. Andrew Levin, who serves on the Issuer's board of directors.

Stakeholder Impact

• Shareholders may experience increased volatility due to the institutional sell-off.
• The reduction in ownership by a major stakeholder may influence market sentiment regarding the company's valuation.

Next Steps

• Continued monitoring of future Form 4 filings to determine if RA Capital intends to further reduce its position.

Key Dates

Recommendation

While institutional selling is a bearish signal, it is often part of routine portfolio rebalancing; investors should hold until further clarity on the company's clinical milestones is provided.

Keywords

Vor Biopharma, VOR, RA Capital Management, Insider Trading, Form 4, Biotech, Institutional Selling